Scholarlink

Background <p>There is a need to better reflect the patient experience in multiple myeloma (MM), beyond just clinical progression, with the use of a novel endpoint that combines disease progression with patient-reported outcomes.</p> Methods <p>A systematic literature review (SLR) identified relevant MM symptoms, which were narrowed down by experts using a Delphi panel. A post-hoc analysis of the MagnetisMM-3 trial of elranatamab assessed the impact of change in patient-reported outcomes (PROs) on the risk of disease progression or death. A composite endpoint for symptomatic progression-free survival (SPFS) combined these symptoms and PFS (PFS event plus 10-point worsening in pain, fatigue, or poor mobility within 28 days).</p> Results <p>The SLR identified 16 symptoms from 34 publications. Delphi consensus was that drowsiness, fatigue, pain, and poor mobility are linked to disease progression. Three symptoms had a significant association with PFS: A 10-point worsening on the 100-point scales for pain, fatigue, and poor mobility corresponded to a 22%, 20%, and 31% increase in risk of progression, respectively. Median SPFS was not reached (95% CI 12.2- not reached).</p> Conclusions <p>SPFS is the first composite endpoint in MM that combines PFS and clinically relevant PROs. The patient-centric approach in the conception of this endpoint allows for a nuanced and comprehensive understanding of the MM patient experience.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月8日

查看全文
  • Martin Kortüm,
  • Sebastian Theurich,
  • James Farrell,
  • Graham Jackson,
  • Gordon Cook,
  • Joseph C. Cappelleri,
  • Olivia Ashman,
  • Shanti Neff-Baro,
  • Aline Gauthier,
  • Khalil Jewiti-Rigondza,
  • Alaeddine Sidhom,
  • Ashraf Chaudhary,
  • Christof Scheid

摘要

Background

There is a need to better reflect the patient experience in multiple myeloma (MM), beyond just clinical progression, with the use of a novel endpoint that combines disease progression with patient-reported outcomes.

Methods

A systematic literature review (SLR) identified relevant MM symptoms, which were narrowed down by experts using a Delphi panel. A post-hoc analysis of the MagnetisMM-3 trial of elranatamab assessed the impact of change in patient-reported outcomes (PROs) on the risk of disease progression or death. A composite endpoint for symptomatic progression-free survival (SPFS) combined these symptoms and PFS (PFS event plus 10-point worsening in pain, fatigue, or poor mobility within 28 days).

Results

The SLR identified 16 symptoms from 34 publications. Delphi consensus was that drowsiness, fatigue, pain, and poor mobility are linked to disease progression. Three symptoms had a significant association with PFS: A 10-point worsening on the 100-point scales for pain, fatigue, and poor mobility corresponded to a 22%, 20%, and 31% increase in risk of progression, respectively. Median SPFS was not reached (95% CI 12.2- not reached).

Conclusions

SPFS is the first composite endpoint in MM that combines PFS and clinically relevant PROs. The patient-centric approach in the conception of this endpoint allows for a nuanced and comprehensive understanding of the MM patient experience.